Clinical Trials
3 trialsNCT05694819 2026-04-08
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
National Cancer Center Hospital East
Phase 2 Completed
NCT06145308 2026-04-02
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT03942653 2025-12-31
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
Big Ten Cancer Research Consortium
Phase 2 Recruiting